MARKET

VIRI

VIRI

Virios Therapeutics Inc
NASDAQ
0.5124
+0.0325
+6.77%
After Hours: 0.5064 -0.006 -1.17% 19:09 04/12 EDT
OPEN
0.4631
PREV CLOSE
0.4799
HIGH
0.5278
LOW
0.4631
VOLUME
372.23K
TURNOVER
0
52 WEEK HIGH
2.420
52 WEEK LOW
0.2790
MARKET CAP
9.87M
P/E (TTM)
-1.8164
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at VIRI last week (0401-0405)?
Weekly Report · 5d ago
Weekly Report: what happened at VIRI last week (0325-0329)?
Weekly Report · 04/01 11:54
12 Health Care Stocks Moving In Monday's Pre-Market Session
Landos Biopharma (NASDAQ:LABP) shares moved upwards by 181.6% to $22.05 during Monday's pre-market session. Altamira Therapeutics shares rose 49.71% after their Q4 earnings report came out yesterday. Neuronetics stock increased by 18.19% in pre- market.
Benzinga · 03/25 13:05
Weekly Report: what happened at VIRI last week (0318-0322)?
Weekly Report · 03/25 11:58
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Cannabis legalization, drug approval, a delisting update and more are the biggest pre-market stock movers on Monday morning. Next e GO stock is rocketing more than 127% alongside heavy pre- market trading this morning. Salarius Pharmaceuticals shares are surging over 28% following cannabis legalization in Germany. The top 10 biggest losers include a company undergoing a reverse stock split.
Investorplace · 03/25 11:36
12 Health Care Stocks Moving In Friday's Intraday Session
IMAC Hldgs (NASDAQ:BACK) shares moved upwards by 91.5% to $2.47 during Friday's regular session. The company's Q4 earnings report came out yesterday. Virios Therapeutics shares increased by 37.98% and Ontrak shares rose by 35.03% in the same session.
Benzinga · 03/22 17:31
12 Health Care Stocks Moving In Thursday's Pre-Market Session
10 Bioscience (NASDAQ:YTEN) stock increased by 133.7% to $0.57 during Thursday's pre-market session. The company's market cap is at $5.2 billion. Immunovant and argenx stock moved upwards by 14.0% and 13.24% respectively. Losers Tourmaline Bio and Avinger stock decreased by 33.4% during the pre- market session.
Benzinga · 03/21 13:05
Weekly Report: what happened at VIRI last week (0311-0315)?
Weekly Report · 03/18 11:56
More
About VIRI
Virios Therapeutics, Inc. is a development-stage biotechnology company. The Company is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (FM) and Long-COVID (LC). Its lead candidate, IMC-1, is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination, dual mechanism antiviral therapy designed to synergistically suppress herpes virus activation and replication, with the end goal of reducing viral mediated disease burden. IMC-2 is a combination of valacyclovir and celecoxib that is believed to have specific activity against Epstein-Barr virus (herpesvirus HHV-4), as well as other herpesviruses. IMC-1 and IMC-2 combine two specific mechanisms of action purposely designed to inhibit herpesvirus activation and replication, thereby converting activated herpesvirus back to dormancy and/or by keeping the herpesvirus in a latent or dormant state.

Webull offers Virios Therapeutics Inc stock information, including NASDAQ: VIRI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIRI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VIRI stock methods without spending real money on the virtual paper trading platform.